A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
NCT04669665
Completed
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/25/2023
Locations: Seelos Investigational Site, Flowood, Mississippi
Conditions: Depressive Disorder, Major, Suicidal
Register for Updates
The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.
NCT02997722
Terminated
This study will evaluate the effect of ketamine on the treatment of patients hospitalized with suicidal thoughts. Half of the patients will receive one dose of ketamine in the vein. The other half will receive a placebo. Because we think that ketamine will improve depression and suicidal thoughts, we expect that patients who receive ketamine will require less time in the hospital than patients who receive placebo.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/18/2020
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Suicidal Ideation
Register for Updates